First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top ...

Both regimens “can be considered standard chemotherapy options” for high-risk, HR-positive early breast cancer, said Sherko Kuemmel, MD, PhD.

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...